Revalia Bio Secures $26.7 Million ARPA-H Award to Revolutionize Drug Development with Human Data Trials
核心洞察
Revalia Bio (搜索) received up to $26.7 million from ARPA-H (搜索) to develop AI-driven models using donated human organs and organ-on-chip platforms for drug safety and efficacy prediction.
The Human Data Trial platform (搜索) aims to reduce reliance on animal testing by generating trial-quality data from functional human organs maintained under clinical conditions.
The CATALYST program (搜索) seeks to accelerate safer drug development by enabling more accurate predictions of safety and efficacy in investigational new drugs before clinical trials.
Revalia Bio (搜索) announced it has been awarded up to $26.7 million under the Advanced Research Projects Agency for Health (ARPA-H (搜索)) Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program. The New Haven-based company will serve as technical lead for the project titled "An Integrated Human Data Approach to Unlock the Future of In Silico Learning Models," marking a significant milestone in human-centered drug development.
Transforming Drug Development with Human Biology
The funding supports Revalia's Human Data Trial platform (搜索), which utilizes donated human organs maintained under clinical conditions to generate trial-quality data on drug safety, efficacy, and mechanism of action. This approach represents a fundamental shift from traditional animal testing models toward human-first methodologies.
"This award is a turning point for Revalia and for the broader field of human-based trials," said Greg Tietjen, PhD, CEO and Co-Founder of Revalia. "It's a validation for us that confirms that the era for human data is here. Donated human organs are the Rosetta Stone of human-centered development, and our Human Data Trials platform transforms that gift into actionable insight for safer, more effective drugs."
The ARPA-H (搜索) CATALYST program (搜索), led by Acting Deputy Director Andy Kilianski, Ph.D., is designed to accelerate safer, faster drug development by enabling more accurate predictions of safety and efficacy in investigational new drugs (INDs). Revalia's approach aligns with recent NIH and FDA initiatives to reduce reliance on animal testing by providing rigorous, clinically grounded human datasets to support regulatory innovation.
Advanced AI Models and Human Data Integration
Revalia will lead efforts to build advanced AI-driven models trained on Human Data Trials, living systems derived from donated human organs, organ-on-chip platforms, and multimodal datasets. The goal is to better predict how drugs behave in the human body, potentially cutting costly late-stage failures and accelerating the delivery of safer therapies to patients.
"Drugs should be tested in the same biology, from the same patients, they are meant to treat," said Janet Nikolovski, PhD, Chief Data and Innovation Officer at Revalia. "We are generating a unique, integrated human dataset encompassing everything from high level patient data to organ specific physiology and comprehensive molecular level analyses. These data will train models that we believe will better simulate clinical outcomes and reduce the risk of drug failure in clinical trials."
National Consortium and the Human Data Stack
The Human Data Trials platform forms the foundation of Revalia's broader Human Data Stack, a framework that integrates donor organs, organoids, and organ-on-chip systems into a unified translational system. The company will collaborate with a national consortium that includes:
- A leading engineering research institute developing high-dimensional datasets through advanced platforms
- A regional nonprofit organization focused on expanding access to organ donation for scientific study
- An academic research lab specializing in artificial intelligence and machine learning to unlock predictive insights
- A top 10 pharmaceutical company looking to integrate New Approach Methodologies (NAMs) into their standard workflows
"This project unites clinicians, biologists, engineers, and AI/ML experts to build advanced in silico models of human physiology that predict drug metabolism, pharmacokinetics, and toxicity," said Nabil Boutagy, PhD, Director of Human Data Trial Operations at Revalia. "By integrating diverse expertise and generating multi-omic data at scale, we aim to cut drug development costs and timelines while guiding optimal dosing for patients."
Honoring Donor Legacy Through Scientific Innovation
Beyond the technical achievements, Revalia emphasizes the profound mission underlying their work. "Most importantly, this program allows us to further deliver on our mission to honor the legacy of every donor by turning the loss of one life into knowledge that shapes the future of medicine," Tietjen noted.
The CATALYST award represents a significant validation of human-centered approaches to drug development, potentially transforming how the pharmaceutical industry approaches safety and efficacy testing while reducing development timelines and costs.